{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/105336928"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ " Company Limited; the costs and time required to complete additional clinical, nonclinical or other requirements prior to any resubmission of the Contrave NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to maintain sufficient capital to fund our operations through potential approval of Contrave in 2014; Orexigen's ability to enter into a collaborative partnership for Cont" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "biospace.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/417949584"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/105336928"] } } }
